Metformin sensitizes arsenic trioxide to suppress intrahepatic cholangiocarcinoma via the regulation of AMPK/p38 MAPK-ERK3/mTORC1 pathways. The gene discussed is MAPK6; the disease is intrahepatic cholangiocarcinoma.